Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.09 USD | +1.99% | -11.21% | -27.55% |
05-09 | Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
05-09 | Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.55% | 2.13B | |
+52.36% | 58.06B | |
-3.86% | 40.53B | |
+36.56% | 38.99B | |
-12.01% | 26.56B | |
+14.13% | 26.7B | |
-21.62% | 18.98B | |
+0.21% | 12.17B | |
+25.96% | 11.92B | |
+23.02% | 12B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Chardan Trims Price Target on Intellia Therapeutics to $107 From $111, Maintains Buy Rating